Key Laboratory of Health Technology Assessment, National Health Commission (Fudan University)

WHO Collaborating Centre for Health Technology Assessment and Management

CHIAS

NEWSLETTER

April 2022 / Issue 1



HIGHLIGHTS

ISPOR and HTAi News

ISPOR AND HTAI NEWS

MORE PATIENT-CENTRIC HEALTHCARE SYSTEM


January 10, 2023, Value in Health, the official journal of ISPOR, announced the publication of a series of articles that promotes an understanding of patient-reported experience measures and their role in healthcare. The use of patient-reported measures in routine clinical settings is rapidly expanding because many healthcare systems are moving towards patient-centered care. In addition to clinically reported outcome measures, the experience of the care process matters too. Patient-reported experience measures have become an important tool for policy makers who wish to understand how well healthcare delivery is aligned with patients' goals. Compared with health preference research, patient-reported experience measures provide a fuller picture of how well a healthcare system meets the needs of patients by combining indicators at the individual and organizational level.

2023 / ISSUE 1

HEOR LEARNING LAB™

January 17, 2023, ISPOR announced the launch of a new educational resource for the field of health economics and outcomes research (HEOR)—HEOR Learning Lab™. It provides unlimited, on-demand, educational video content to facilitate learning and innovative approaches in the field from the leading global organization in HEOR. HEOR Learning Lab offers high-value content selected from the Society's conferences, summits, and other seminal events. Content is focused on the most topical themes impacting the field, including real-world evidence, patient-centered research, digital health, artificial intelligence and machine learning, health technology assessment, economic methods, healthcare financing, access and policy, learning healthcare systems, and much more.

Additional information can be found at: https://www.ispor.org/welcome-HEOR-Learning-Lab?utm_medium=press_release&utm_source=public&utm_campaign=general_ispor&utm_content=heor-learninglab_jan17.



ISPOR ROADMAP FOR PATIENT PREFERENCES IN DECISION MAKING

John F P Bridges, Esther W de Bekker-Grob, Brett Hauber and others published a paper titled "A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force "in the "Value Health" magazine in February 2022 ("A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force ", original link:

https://pubmed.ncbi.nlm.nih.gov/36754539/). The article introduced the ISPOR Roadmap for Patient Preferences in Decision Making, which illustrated 5 important areas where patient-preference researchers should work with stakeholders.

Patient preference studies are important because they promote patient centricity by engaging directly with real patients to inform the tradeoffs they are willing to make with treatment risks versus benefits. Patient preferences are also important to understand how patients value nonhealth outcomes. At the population level, patient preference research informs healthcare value assessments, resource allocation, public health programs, and shared decision making. The ISPOR Roadmap highlights how that usefulness and impact will be maximized when patient-preference researchers work with decision makers, patients and patient groups, and other stakeholders across 5 key areas: (1) Context; (2) Purpose; (3) Population; (4) Method; and (5) Impact. The ISPOR Roadmap is methods agnostic and will aid researchers and improve studies regardless of the preference method used.

Although the authors conceptualize the construct as a roadmap, they do not intend to suggest that it must be followed linearly. Rather, these are 5 broad considerations that can help those conducting preference research to enhance the likelihood of impacting decision making and being able to identify the impacts (both intended and unintended) that their studies have made.



DRUG PRICING CONUNDRUM

March 6, 2023—Value in Health, the official journal of ISPOR, announced the publication of a series of articles describing important new research related to drug pricing globally. Increases in drug prices and drug spending are of concern to health systems worldwide. In fact, surveys of ISPOR members have consistently identified drug pricing as one of the top 10 health economics and outcomes research issues affecting healthcare decision making and accessibility to innovative treatments. This has naturally driven policy interest and discussion around drug pricing and the need to balance affordability with sustaining innovation. Because of this, the journal Value in Health agreed to the creation of this themed section, and an open call was made on the journal's website for submissions presenting quantitative or methodological analyses relating to drug pricing throughout the product life cycle. Different research papers in this issue present quantitative research on both branded and generic drug prices showing their relationship to the value generated by these drugs as well as their relationship to patent expiry and market competition. It is clear that the costs associated with developing, producing, and marketing innovative drugs must be balanced against the societal value of the drug to determine a price that gives an acceptable rate of return to the supplier and to society.

HTAI NEWS

The nomination and election of the nominating committee of the International Health Technology Assessment Association (HTAI) in 2023 will be open from February 14 to March 1 for one vice president with a total commitment of six years position (2023-2029) and three positions of director with a term of three years (2023-2026). The HTAi Board seeks to ensure that, as a whole, it reflects the diversity of our membership and includes the skills, experience, expertise, knowledge, perspectives, education, age, gender, ethnicity, and attributes necessary to effectively oversee the operations and long-term strategy of the HTAi Society. Candidates for the 2023 Board of Directors Election were announced on March 27. For more information, see the webpage: https://htai.org/candidates-for-the-2023-board-of-directors-election/.

In webinar, at 8:00 a.m (4:00 p.m. Berlin time) on January 11, the speaker Milou Hogervorst hold a webinar on the theme of "i-HTS Presents Handling the Uncertainty in Health Technology Assessment". For more information, see the webpage: https://htai.org/event/webinar-handling-the-uncertainty-in-health-technology-assessment/. Then, at 1:00 a.m (9:00 a.m. Berlin time) on January 17 and February 14, the speaker Milou Hogervorst hold a webinar on the theme of "i-HTS presents Guidelines and training, appropriate use of health technologies" and "i-HTS and HTAi – Introduction of Early Awareness, Early Dialogue, Early Advice and Scientific Advice" respectively. For more information, see the webpage: https://htai.org/event/8347/.

The HTAi Asia Policy Forum Organizing Committee and Latin America Policy Forum Organizing Committee opened a call for nominations to fill a for-profit and a not-for-profit vacancy since January 6 and January 27 respectively. Members are required to commit to continued and diligent support of the content and development of Policy Forum meetings through input on the topic, agenda, the research, framing and reporting of the pre-meeting background paper, the identification of speakers, and several outputs of the meeting. The term of office for member organization representatives is three years and can be extended up to a further three years only, for a maximum six year term. For more information, see the webpage: https://htai.org/htai-asia-policy-forum-organizing-committee-opens-call-for-nominations/.

The 2023 Global Policy Forum (GPF) was held at Hague, Netherlands, from March 26 to 28. The meeting will centre around the 2023 Global Policy Forum background paper, "The Value and Impact of Health Technology Assessment".

The HTAi Real World Evidence & Artificial Intelligence (RWE-AI) Interest Group and Information Retrieval Interest Group (IRG) opened call for Technical Officers sine February 24 and March 3 respectively. Technical Officers fulfill responsibilities such as defining agendas, setting calls and taking minutes, writing reports, supporting project work and scientific papers, drafting press releases and other similar activities. The IRG work for individuals who provide information resources, discuss literature search methodology and investigate technologies appropriate to HTA work. The IRG invites members working in a wide variety of

capacities to support informed decision making by exchanging information and sharing expertise for advancing processes, methodology, and information retrieval tools. For more information, see the webpage: https://htai.org/information-retrieval/. RWE-AI gathers members interested in the generation and use of RWE and/or AI for HTA. The Interest Group provides an environment for education and training, communication and knowledge sharing, and capacity building and collaboration. For more information, see the webpage: https://httai.org/real-world-evidence-and-artificial-intelligence/.



Key Laboratory of Health Technology Assessment, National Health Commission (Fudan University) / WHO Collaborating Centre for Health Technology Assessment and Management

April 2022 / Issue 1 Editor: Yuliang Xiang P. O. Box 197, No 138, Yi Xue Yuan Road, Shanghai, 200032

Tel: 86-21-33565190

Email: cwchen@shmu.edu.cn

Website: https://chta.fudan.edu.cn/